Clinical trials: Camrelizumab
Nasopharyngeal Carcinoma
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
This is a multicenter, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT combined with programmed death 1 (PD-1) antibody and chemotherapy in nasopharyngeal…
- Trial name
- NCT05524168
- Testing
- SBRT, Camrelizumab, Gemcitabine
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sun Yat-sen University
Advanced Hepatocellular Carcinoma
Camrelizumab Utilization on Patients With Advanced Liver Cancer
To observe and evaluate the safety and efficacy of camrelizumab in advanced liver cancer
- Trial name
- NCT04487704
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Advanced Solid Tumors
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects
This is an open-label, multiple centers, non-randomized, dose escalation phase I trial to evaluate safety and tolerability of SHR-1210 in patients with advanced solid tumors The primary objective is to assess safety and…
- Trial name
- NCT02721589
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II
Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer
The goal of this clinical trial is to test a new combination treatment for locally advanced rectal cancer (cancer in the lower or middle part of the rectum that has not spread to distant organs).
- Conditions
- Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- NCT07397442
- Testing
- Short-Course Radiotherapy Combined with Chemotherapy and Immunotherapy
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Beijing Friendship Hospital
Immune-related Adverse Event, Malignant Solid Tumors
The Effect of Serum Ferritin in irAE
This is a prospective clinical study to clarify serum ferritin as a biomarker for the diagnosis, differential diagnosis and prognosis of immune-related adverse event(irAE).
- Conditions
- Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia, Serum Ferritin
- Trial name
- NCT06702566
- Testing
- PD-1 and PD-L1 inhibitor, Targeted drugs, chemotherapy drugs
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
To evaluate the efficacy and safety of camrelizumab and chemotherapy with or without anlotinib as first-line treatment for advanced gallbladder cancer and extrahepatic cholangiocarcinoma
- Trial name
- NCT06901622
- Testing
- Camrelizumab, anlotinib, nab-paclitaxel, S-1, Camrelizumab, nab-paclitaxel, S-1
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
NSCLC Stage IV
Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer
Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.
- Trial name
- MWA in NSCLC (NCT04102982)
- Testing
- Camrelizumab, Camrelizumab plus microwave ablation
- Where
- 13 sites in China
- Volunteers
- 200 people
- Sponsor
- Shandong Provincial Hospital
Hepatocellular Carcinoma
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
This study is an open-label, single-arm prospective clinical trial that evaluates the efficacy and safety of neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib in the treatment of…
- Trial name
- NCT06349317
- Testing
- Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Yongyi Zeng
Neoadjuvant Chemotherapy, PD-1 Antibody
Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer
Based on various external factors and differences in the basic characteristics of patients, in my country, it is not clear whether concurrent chemoradiotherapy can achieve optimal therapeutic effect in patients with…
- Conditions
- Neoadjuvant Chemotherapy, PD-1 Antibody, Radiotherapy, Cervical Cancer
- Trial name
- PD-1 (NCT05554276)
- Testing
- neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Nasopharyngeal Carcinoma
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
This study aims to explore a new, more effective and tolerable treatment regimen for patients with advanced recurrent/metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05854849
- Testing
- Camrelizumab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
Hepatic resection is the most effective curative treatment for resectable HCC, whereas frequent recurrence usually impaired the efficacy of hepatic resection and contributed poor survivals.
- Trial name
- NCT03914352
- Testing
- PD-1 antibody, TACE
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cancer Hospital of Guangxi Medical University
Osteosarcoma, Survival
Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma
Treatment strategies for high-grade osteosarcoma with multidrug chemotherapy and resection result in 3-year event-free survival of 60-70%.
- Conditions
- Osteosarcoma, Survival, Chemotherapy Effect, Toxicity, Drug
- Trial name
- MAPAC (NCT04351308)
- Testing
- MAPI chemotherapy, Apatinib Mesylate, Camrelizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Extranodal NK/T-cell Lymphoma, Nasal Type
SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma
This is an open-label, multi-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 in subjects with relapsed or refractory extranodal NK/T cell lymphoma.Efficacy will be assessed every 8 weeks according…
- Trial name
- NCT03363555
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma, Oligometastasis
Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma
The main purpose of this study is to see how well the experimental drug camrelizumab(SHR-1210) works in people with oligometastatic NPC who have already had locally radiotherapy for their disease.
- Conditions
- Nasopharyngeal Carcinoma, Oligometastasis, Radiotherapy
- Trial name
- NCT04221516
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Salivary Gland Carcinoma, Precision Therapy
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and…
- Trial name
- NCT06145308
- Testing
- Cohort 1 (HER2-positive, RC48-ADC), Cohort 2 (NTRK-fusion or NTRK-mutant), Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Peking Union Medical College
Hepatocellular Carcinoma
TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT
Hepatocellular carcinoma (HCC) is characterized with vascular invasion, particularly of the portal vein, resulting in portal vein tumor thrombus (PVTT) in 10%-40% of HCC patients at the time of HCC diagnosis.
- Trial name
- NCT05535998
- Testing
- TACE-HAIC, TACE, Targeted therapy
- Where
- China
- Volunteers
- 743 people
- Sponsor
- Yunfei Yuan
Second Line Treatment of Gastric Cancer
Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
This study is a multicenter, open, and randomized clinical phase II exploratory study. The "pick the winner" study design is used to determine and select which chemotherapy drug (irinotecan vs.
- Trial name
- NCT05669807
- Testing
- Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan
- Volunteers
- 184 people
- Sponsor
- Zhejiang Cancer Hospital
Hypopharyngeal Carcinoma, Immunotherapy
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma
This is a single-center, multidisciplinary, open-label, single-arm prospective clinical study.
- Conditions
- Hypopharyngeal Carcinoma, Immunotherapy, Chemotherapy
- Trial name
- NCT04156698
- Testing
- Docetaxel, Cisplatin, Capecitabine
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Non Hodgkin Lymphoma
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor
This is a Phase I/II clinical trial for patients with r/r Non-Hodgkin's Lymphoma relapsed after chimeric antigen receptor T cells infusion.
- Trial name
- NCT04337606
- Testing
- Chidamide, Decitabine, Camrelizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Cervical Carcinoma, Chemoradiotherapy
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
This study is a single-center, single-arm, open-phase II clinical study, the main purpose of which is to evaluate the effectiveness and safety of camrelizumab combined with concurrent chemoradiotherapy for early and locally…
- Conditions
- Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1, Immunotherapy
- Trial name
- NCT05311566
- Testing
- Camrelizumab plus Concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Lei Li